Vertex Pharmaceuticals Stock Rises 8.3% on Povetacicept's 50% Proteinuria Reduction
Vertex Pharmaceuticals announced that its experimental kidney disease drug povetacicept achieved a 50% reduction in proteinuria versus placebo in a late-stage IgA nephropathy trial, meeting its primary endpoint. Shares jumped 8.3% and the company plans to submit an accelerated approval application by month end.
1. Late-Stage Trial Success
Povetacicept, Vertex’s experimental therapy for IgA nephropathy, achieved a statistically significant 50% reduction in proteinuria compared with placebo in an interim analysis of a late-stage trial, fulfilling its primary endpoint and marking a pivotal diversification step beyond cystic fibrosis products.
2. Market Reaction and Analyst Upgrades
Following publication of the trial data, Vertex shares surged 8.3%, reflecting investor confidence; analysts at BMO Capital and Cantor Fitzgerald responded by raising their price targets, highlighting the treatment’s commercial potential.
3. Accelerated Approval Filing Plans
Vertex confirmed plans to complete and submit an accelerated approval application to U.S. regulators by the end of the month, aiming to expedite market access for povetacicept pending regulatory review.